Recombinant CD79B (Polatuzumab Biosimilar) anticorps

N° du produit ABIN7795113

L’anticorps Humanized Monoclonal anti-CD79B (Polatuzumab Biosimilar) a été validé pour FACS et in vivo. Il convient pour détecter CD79B (Polatuzumab Biosimilar) dans des échantillons de Humain.

Aperçu rapide pour Recombinant CD79B (Polatuzumab Biosimilar) anticorps (ABIN7795113)

Antigène: CD79B (Polatuzumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp CD79B (Polatuzumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-CD79B (Polatuzumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody

Attributs du produit: What is polatuzumab biosimilar research grade? Polatuzumab is a humanized IgG1-kappa monoclonal antibody against the human CD79B protein, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma (DLBCL) after at least two other cancer treatments did not work or have stopped working. It is given in combination with bendamustine (Bendeka, Treanda) and a medicine that contains rituximab (Rituxan). Polatuzumab vedotin works by attaching to CD79b and releasing a toxic substance that kills the cancer cells. Polatuzumab biosimilar uses the same protein sequences as the therapeutic antibody polatuzumab.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human CD79B

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur CD79B (Polatuzumab Biosimilar)

Antigène: CD79B (Polatuzumab Biosimilar)

Autre désignation: Polatuzumab Biosimilar

Classe de substances: Biosimilar